![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 284, Issue 1, 103-110, 1998
Departments of
Cardiovascular Research (R.Y, S.B., A.K., N.F.,
H.J.) and
Pharmacokinetics and Metabolism (B.A.K., N.B.M., T.F.Z.),
Genentech, Inc., South San Francisco, California
Vascular endothelial growth factor (VEGF) produces beneficial
angiogenesis in animal models of coronary and peripheral ischemia. However, intravenous bolus injection of Chinese hamster ovary cell
(CHO)-derived VEGF produces adverse effects on hemodynamics. The
present study examined pharmacokinetic and hemodynamic responses to
Escherichia coli-derived VEGF, which will be used in
clinical patients, compared with responses to CHO-derived VEGF, and
tested whether intravenous infusion of E. coli-derived
VEGF attenuates the hemodynamic responses compared with the responses
observed with intravenous bolus injection. Hemodynamic parameters were measured before and after administration of VEGF in conscious, instrumented rats. Intravenous injection of both CHO- and E.
coli-derived VEGF produced a similar maximal reduction in
arterial pressure, although E. coli-derived VEGF
exhibited less of a depressor effect in the initial phase after
injection. Either infusion or injection of E.
coli-derived VEGF caused hypotension, tachycardia and reduced cardiac output and stroke volume, which were significantly attenuated when given by infusion compared with injection. The maximal hypotensive and tachycardic responses to infusion were decreased by 50 to 60%
compared with those responses observed after injection. Cardiac output
was maximally reduced by 34% after injection, but only 18% after
infusion. A sustained elevation in systemic vascular resistance
observed after injection was avoided after infusion. Thus, the
hemodynamic side effects of VEGF administration can be substantially
attenuated by controlling the rate of VEGF infusion. The data indicate
that infusion, instead of bolus injection, is a more appropriate
regimen for VEGF administration.
This article has been cited by other articles:
|
|
 |
|
  J. O. Curwen, H. L. Musgrove, J. Kendrew, G. H.P. Richmond, D. J. Ogilvie, and S. R. Wedge Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy Clin. Cancer Res., May 15, 2008; 14(10): 3124 - 3131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Trousdale, S. V. Pollak, J. Klein, L. Lobel, Y. Funahashi, N. Feirt, and J. W. Lustbader Single-Chain Bifunctional Vascular Endothelial Growth Factor (VEGF)-Follicle-Stimulating Hormone (FSH)-C-Terminal Peptide (CTP) Is Superior to the Combination Therapy of Recombinant VEGF plus FSH-CTP in Stimulating Angiogenesis during Ovarian Folliculogenesis Endocrinology, March 1, 2007; 148(3): 1296 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Jin, R. Yang, W. Li, A. K. Ogasawara, R. Schwall, D. A. Eberhard, Z. Zheng, D. Kahn, and N. F. Paoni Early Treatment with Hepatocyte Growth Factor Improves Cardiac Function in Experimental Heart Failure Induced by Myocardial Infarction J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 654 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Li, A. K. Ogasawara, R. Yang, W. Wei, G.-W. He, T. F. Zioncheck, S. Bunting, A. M. de Vos, and H. Jin KDR (VEGF Receptor 2) Is the Major Mediator for the Hypotensive Effect of VEGF Hypertension, June 1, 2002; 39(6): 1095 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-H. Liu, H. Jin, H. S. Floten, Z. Ren, A. P.C. Yim, and G.-W. He Vascular endothelial growth factor-mediated, endothelium-dependent relaxation in human internal mammary artery Ann. Thorac. Surg., March 1, 2002; 73(3): 819 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Lin, J. LeCouter, J. Kowalski, and N. Ferrara Characterization of Endocrine Gland-derived Vascular Endothelial Growth Factor Signaling in Adrenal Cortex Capillary Endothelial Cells J. Biol. Chem., March 1, 2002; 277(10): 8724 - 8729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Yang, A. K. Ogasawara, T. F. Zioncheck, Z. Ren, G.-W. He, G. G. DeGuzman, N. Pelletier, B.-Q. Shen, S. Bunting, and H. Jin Exaggerated Hypotensive Effect of Vascular Endothelial Growth Factor in Spontaneously Hypertensive Rats Hypertension, March 1, 2002; 39(3): 815 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. LECOUTER, R. LIN, and N. FERRARA The Role of EG-VEGF in the Regulation of Angiogenesis in Endocrine Glands Cold Spring Harb Symp Quant Biol, January 1, 2002; 67(0): 217 - 222. [Abstract] [PDF]
|
|
|
|
|
|
M.-H. Liu, H.-K. Jin, H. S. Floten, Q. Yang, A. P. C. Yim, A. Furnary, T. F. Zioncheck, S. Bunting, and G.-W. He Vascular Endothelial Growth Factor-Mediated Endothelium-Dependent Relaxation Is Blunted in Spontaneously Hypertensive Rats J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 473 - 477. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Jin, R. Yang, T. A. Awad, F. Wang, W. Li, S.-P. Williams, A. Ogasawara, B. Shimada, P. M. Williams, G. de Feo, et al. Effects of Early Angiotensin-Converting Enzyme Inhibition on Cardiac Gene Expression After Acute Myocardial Infarction Circulation, February 6, 2001; 103(5): 736 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. SCALIA, G. BOOTH, and D. J. LEFER Vascular endothelial growth factor attenuates leukocyte–endothelium interaction during acute endothelial dysfunction: essential role of endothelium-derived nitric oxide FASEB J, June 1, 1999; 13(9): 1039 - 1046. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
